

CLAIMS

1. The use of an anti-calnexin (anti-CNX) antibody for the manufacture of a medicament for the treatment or prevention of cartilage degradation in a subject.

5

2. The use of claim 1, wherein the subject has arthritis.

3. The use of claim 2, wherein the arthritis is selected from osteoarthritis, rheumatoid arthritis, psoriasis arthritis, juvenile idiopathic arthritis (JIA), and arthritic flares.

10

4. The use any previous claim, wherein the cartilage degradation is in one or more joints.

5. The use of any previous claim, wherein the cartilage degradation is characterised by increased O-glycosylation and/or GALNT Activation (GALA) in joint tissues, cartilage tissue, and/or synovial fibroblasts.

15

6. The use of any previous claim, wherein the cartilage degradation is characterised by increased O-glycosylation of calnexin in joint tissues, cartilage tissue, and/or synovial fibroblasts.

20

7. The use of any previous claim, wherein the cartilage degradation is characterised by increased cell surface expression of calnexin in joint tissues, cartilage tissue, and/or synovial fibroblasts.

8. The use of any previous claim, wherein the cartilage degradation is characterised by extracellular matrix (ECM) degradation.

25

9. The use of any previous claim, wherein the cartilage degradation is mediated by the activity of synovial fibroblasts.

10. The use of any previous claim, wherein the anti-CNX antibody is capable of reducing:

30

- (a) ECM degradation; or
- (b) an oxireductase activity; or
- (c) a disulphide bond reductase activity.

11. The use of any previous claim, wherein the antibody is monoclonal.

35

12. The use of any previous claim, wherein the anti-CNX antibody is to be administered together, separately, or sequentially with an anti-rheumatic drug.

13. The use of any previous claim, wherein a subject is determined to be suitable for treatment with the anti-CNX antibody through the following steps:

- i. detecting the level of Tn glycan in a synovial fibroblast sample;
 - 5 ii. comparing the level of Tn glycan in step (i) with the level of Tn glycan in a synovial fibroblast sample from a control group;
- wherein an increase in the level of Tn glycan present in the sample compared to the control group is indicative of the suitability for treatment.

10 14. The use of any previous claim, wherein a subject is determined to be suitable for treatment with the anti-CNX antibody through the following steps:

- i. detecting the level of CNX cell surface expression in a synovial fibroblast sample;
- ii. comparing the level of CNX cell surface expression in step (i) with the level of CNX cell surface expression in a synovial fibroblast sample from a control group;
- 15 wherein an increase in the level of CNX cell surface expression present in the sample compared to the control group is indicative of the suitability for treatment.

15. The use of any previous claim, wherein a subject is determined to be suitable for treatment with the anti-CNX antibody through the following steps:

- 20 i. detecting the level CNX glycosylation in a synovial fibroblast sample;
 - ii. comparing the level of CNX glycosylation in step (i) with the level of CNX glycosylation in a synovial fibroblast sample from a control group;
- wherein an increase in the level of CNX glycosylation present in the sample compared to the control group is indicative of the suitability for treatment.